Ranbaxy vs Dr. Reddy's: Which one is better? - II - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Ranbaxy vs Dr. Reddy's: Which one is better? - II

Mar 26, 2011

In the previous article, we compared Ranbaxy and Dr Reddy's on their business segments. Moving a step ahead, let us now focus on the revenues segmentation and some other financial parameters.

Revenue Segmentation

The revenue of Ranbaxy was about Rs 70 bn in CY09, while that of Dr Reddy's was about Rs 75 bn FY10. Even though, Ranbaxy and Dr Reddy are Indian companies, the revenue for both comes from diverse geographies. 67% of Dr Reddy's total revenues come from North America, Europe, Russia and the CIS while that from Ranbaxy is 50%. India's contribution to the top line of both companies is around 20% only.


Revenue growth and EBITDA margins

The total revenue growth for pharma companies year after year cannot give us a true picture as there are times when generic pharma companies reap benefits of the 180 day exclusivity period. The company getting this exclusivity will gain higher volumes and margins only for the period of 180 days. Post which the competition will hamper prices as well as revenues.


In CY07, Ranbaxy's global sales recorded a robust growth leading to a 10% increase in total revenues. But for CY08 and CY09, the revenue growth was muted. This impact on the business could be attributed to the financial crises of 2008 and the US FDA imposing a ban on two of its manufacturing facilities at Dewas and Poanta Sahib. However in CY09, the company was able to launch three First-To-File (FTF) products from its US facilities and one authorized generic.


Ranbaxy has a strong FTF pipeline but is unable to grab the opportunities due to its issues regarding the manufacturing facilities. But, a point to be noted is that the FDA issue is now two years old and the chances of success are better. Though, as of now, this issue is draining the margins.

The revenue for Dr Reddy's decreased by more than 20% in FY08 as compared to the previous year. This was because there were no new authorized generics or 180 day exclusivity drugs launched in that year, whereas, there were four such successful US generic launches in FY07. The steep rise in revenues in FY09 can be majorly attributed to the launch of Sumatriptan - the authorized generic version of Imitrex in the USA ahead of other competitors. This alone had contributed about 10% tototal revenues in FY09.

EBITDA margin impact in FY08 can be attributed to the difficulties in the change in the structure of the German market after the acquisition of Betapharm in Germany. The new tender based system increased the generic competition drastically and the realizations fell steeply too.


R&D costs for both the companies are almost in a similar range. But recently, Daiichi Sankyo hived off the new drug discovery research (NDDR) unit from Ranbaxy. This will bring down the research cost quite substantially in the next few years. Dr Reddy's consistently is investing 6% plus of revenues in R&D activities. One of its new chemical entities (NCE) is currently in late phase-III clinical trials.

We can conclude that the revenue contribution for both the companies is quite diverse. The revenue growth in the North American market will be a crucial parameter for Dr Reddy. The margins for Ranbaxy should improve once the issues regarding two of its manufacturing facilities are resolved.

In the next article we will take the comparison further to understand both the companies' balance sheet ratios and price performance.

Ranbaxy vs Dr Reddy's Which one is better? - Series - Previous article | Next | All Articles


Equitymaster requests your view! Post a comment on "Ranbaxy vs Dr. Reddy's: Which one is better? - II". Click here!

7 Responses to "Ranbaxy vs Dr. Reddy's: Which one is better? - II"

C N BHATIA

Apr 7, 2011

BOTH THE COMPANIES ARE BETTER DUE TO THEIR MANAGEMENT

Like 

DEV RAINA

Apr 4, 2011

the analysis may be less elaborate than the given but please make the picture clear and emphatic as to which is better nad why ,may be in a snippet.

Like 

Ramlal mundhra

Apr 3, 2011

I agree with the views of Mr Aditya. When U reaserch why cant the full article be posted on one go.

Like 

ADITYA

Apr 1, 2011

Where is the 3rd part of the comparision? Part 2 was posted on 26th march, today it is 1st April, the 3rd part is yet to be published. It would have been better to post it as a single article.....

Like 

KRISHNA TUMKUR

Mar 28, 2011

Both the companies are strong indian pharmaceutical companies.Tomorrow as equtymaster keeps harping on CRAMS and it's impact on the pharma sector is going to be crucial ,i do feel Drreddy's has the edge due to it's
superior R&D facilities located in india vis a vis ranbaxy which has to rely on daiichi sankyo.Bulk drug manufacturing will be the key and i do feel drreddy's has the advantage.

Like 

karan

Mar 27, 2011

this comparison does not give any idea. there is lack of substance in this.

Like 

Dr Dilip

Mar 26, 2011

it will b better to give all the details about both companies in one go rather than spreading in many parts and giving them at different time.then we can compare in abetter way.

Like 
  
Equitymaster requests your view! Post a comment on "Ranbaxy vs Dr. Reddy's: Which one is better? - II". Click here!

More Views on News

J.B.CHEMICALS Share Price Up by 6%; BSE HEALTHCARE Index Up 2.3% (Market Updates)

Sep 28, 2020 | Updated on Sep 28, 2020

J.B.CHEMICALS share price is trading up by 6% and its current market price is Rs 1,019. The BSE HEALTHCARE is up by 2.3%. The top gainers in the BSE HEALTHCARE Index are J.B.CHEMICALS (up 6.1%) and LAURUS LABS LTD (up 10.0%). The top losers are BLISS GVS PHARMA (down 0.1%) and ERIS LIFESCIENCES LIMITED (down 0.2%).

BIOCON Share Price Up by 5%; BSE HEALTHCARE Index Up 2.3% (Market Updates)

Sep 28, 2020 | Updated on Sep 28, 2020

BIOCON share price is trading up by 5% and its current market price is Rs 450. The BSE HEALTHCARE is up by 2.3%. The top gainers in the BSE HEALTHCARE Index are BIOCON (up 5.1%) and LAURUS LABS LTD (up 10.0%). The top losers are ALKEM LABORATORIES (down 0.1%) and TORRENT PHARMA (down 0.2%).

STRIDES PHARMA SCIENCE Share Price Up by 5%; BSE HEALTHCARE Index Up 2.3% (Market Updates)

Sep 28, 2020 | Updated on Sep 28, 2020

STRIDES PHARMA SCIENCE share price is trading up by 5% and its current market price is Rs 697. The BSE HEALTHCARE is up by 2.3%. The top gainers in the BSE HEALTHCARE Index are STRIDES PHARMA SCIENCE (up 5.3%) and LAURUS LABS LTD (up 10.0%). The top losers are ERIS LIFESCIENCES LIMITED (down 0.1%) and TORRENT PHARMA (down 0.2%).

DR. LAL PATHLABS LTD Share Price Up by 7%; BSE HEALTHCARE Index Up 2.3% (Market Updates)

Sep 28, 2020 | Updated on Sep 28, 2020

DR. LAL PATHLABS LTD share price is trading up by 7% and its current market price is Rs 1,943. The BSE HEALTHCARE is up by 2.3%. The top gainers in the BSE HEALTHCARE Index are DR. LAL PATHLABS LTD (up 6.6%) and LAURUS LABS LTD (up 10.0%). The top losers are SANOFI INDIA (down 0.1%) and ERIS LIFESCIENCES LIMITED (down 0.1%).

NATCO PHARMA Share Price Up by 5%; BSE HEALTHCARE Index Up 2.0% (Market Updates)

Sep 28, 2020 | Updated on Sep 28, 2020

NATCO PHARMA share price is trading up by 5% and its current market price is Rs 934. The BSE HEALTHCARE is up by 2.0%. The top gainers in the BSE HEALTHCARE Index are NATCO PHARMA (up 5.2%) and LAURUS LABS LTD (up 9.1%). The top losers are ALKEM LABORATORIES and BLISS GVS PHARMA .

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Sep 28, 2020 (Close)

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS